Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amphotericin b deoxycholate + liposomal amphotericin b
- Development stage
- Unknown
- Lead developer
- Vestar
- Modality
- Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
This combination involves two formulations of amphotericin B: amphotericin B deoxycholate, a conventional form, and liposomal amphotericin B, a lipid-associated formulation designed to reduce toxicity. Both are antifungal agents that work by binding to ergosterol in fungal cell membranes, disrupting membrane integrity and leading to cell death. Liposomal amphotericin B is less nephrotoxic and causes fewer infusion-related reactions compared to the conventional form[1][2][5].
02
Targets
Ergosterol
Beyond the preview
Go deeper on amphotericin b deoxycholate + liposomal amphotericin b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amphotericin b deoxycholate + liposomal amphotericin b.